To accelerate the development of the monoclonal gammopathy Vk*-MYC transgenic mice (between 5 and 8 mo of age) were immunized repeatedly (three times separated by 30 d) with 4-hydroxy-3-nitrophenyl-OVA, NP-OVA, a hapten-carrier conjugate known to induce germinal center reactions, until development gammopathy and ultimately multiple myeloma were evident from quantification of IgG and clonotypic M protein, recapitulating disease progression in humans (15, 16). The gene discussed is MYC; the disease is plasma cell myeloma.